Agents stabilizing G-quadruplexes have the potential to interfere with telomere replication by blocking the elongation step catalysed by telomerase or telomerase-independent mechanism and could therefore act as antitumor agents. In this study, we found that quindoline derivatives interacted preferentially with intramolecular G-quadruplex structures and were novel potent telomerase inhibitors. Treatment with quindoline derivatives reproducibly inhibited telomerase activity in human leukemia K562 cells and colon cancer SW620 cells.
Introduction
Telomeres are dynamic DNA-protein complexes that cap the ends of linear chromosomes consisting of TTAGGG repeats and telomere-binding proteins. Telomeres protect the chromosome ends from degradation, recombination and DNA repair activities (Blackburn, 1991; Greider, 1996) . In addition, telomere length is progressively reduced with cell divisions, due to the 'end-replication problem' and the putative exonuclease activity in the CA-rich strand. Telomere shortening in aging cells induces replicative senescence (Reddel, 2000; der-Sarkissian et al., 2004) . When telomeres reach a critical size, chromosomes become unstable and undergo end-to-end fusions, DNA fragmentation, and mutations (Blackburn, 2000 (Blackburn, , 2001 .
Telomerase is the most important enzyme involved in telomere maintenance in tumor cells identified so far (Masutomi et al., 2003; Wong and Collins, 2003) . It is a large RNA-dependent DNA polymerase that uses its own associated RNA template to catalyse the addition of telomeric DNA repeats to the 3 0 -end of the singlestranded DNA telomere (Feng et al., 1995; Nakamura et al., 1997) . Telomerase is expressed in most types of tumor cells but not in most somatic cells, suggesting that telomerase inhibitors may be a powerful new approach to cancer chemotherapy (Kim et al., 1994; Greider, 1996) . A small proportion of tumor cells have an alternative telomere maintenance pathway (alternative lengthening of telomeres, ALT), which appears to be independent of telomerase and involves recombination events (Bryan et al., 1997; Dunham et al., 2000; Read et al., 2001; Schwarze et al., 2001) .
DNA is most often regarded as a duplex molecule in which the two self-complementary strands are held together by Watson-Crick base pairs. However, certain DNA sequences that are purine rich and contain runs of guanines (G) can form four-stranded structures called G-quadruplexes. Such sequences are found at the ends of chromosomes in the so-called telomeric regions and in transcriptional regulatory regions in several important oncogenes. As telomere maintenance mechanisms and the transcriptional regulation of oncogene expression are important targets for drug design, G-quadruplexes represent potentially important targets in drug development (Han and Hurley, 2000; Neidle and Parkinson, 2002) . Several classes of small molecules have been identified to interact with and stabilize G-quadruplexes, including tricyclic anthraquinones (Sun et al., 1997) , fluorenones (Perry et al., 1999b) , substituted acridines (Gowan et al., 2002; Burger et al., 2005) , cationic porphyrins (Ishikawa et al., 2001; Dixon et al., 2005) , telomestatin (SOT-095) (Tauchi et al., 2003) , a perylenetetracarboxylic diimide derivative (Fedoroff et al., 1998) , indoloquinolines (Caprio et al., 2000) , pyridinedicarboxamide derivatives (Pennarun et al., 2005) and a benzonaphthofurandione tetracyclic compound (Perry et al., 1999a) .
Cryptolepine is a naturally occurring quindoline alkaloid. The compound and its hydrochloride salts possess numerous useful biological properties (e.g. antimalarial activity) and have been used as antimalarial drugs in Central and Western Africa for centuries. Cryptolepine is also a rare example of natural products whose preparation reported prior to its isolation from natural resource (Bierer et al., 1998) . Further mechanistic investigation at the molecular level demonstrated that cryptolepine could interact with DNA through intercalation and interfere with the catalytic activity of topoisomerase II (Bonjean et al., 1998; Lisgarten et al., 2002) . Most recent studies further revealed that some structural derivatives of cryptolepine were capable of interacting with G-quadruplex form of DNA and inhibiting the activity of telomerase (Caprio et al., 2000; Schultes et al., 2004) . To explore novel and potent telomerase inhibitors for cancer treatment, we have recently designed and synthesized a new series of quindoline analog in our laboratories. We found that these compounds could interact with and stabilize G-quadruplexes and potentially inhibit telomerase activity and induce senescence in human cancer cell lines.
Results
Induction and stabilization of G-quadruplex structures by quindoline derivatives A series of new quindoline derivatives 4a-4j were designed and synthesized via introducing an electron donor such as an amino group on the 11-position of quindoline (Figure 1 ).
The formation and stabilization of G-quadruplex of DNA promoted by these newly designed molecules was accordingly examined via UV and circular dichroism (CD) spectroscopy. Our results demonstrated that these 11-aminoindoloquindolines were not only able to stabilize G-quadruplex structure but also induced the G-rich telomeric repeats to fold into antiparallel quadruplex. Here, N 0 -(10H-Indolo [3,2-b] quinolin-11-yl)-N, N-dimethyl-propane-1,3-diamine (SYUIQ-5) (quindoline derivative 4c) was selected as a representative to analyse its interaction with G-rich DNA sequence d[G 3 (T 2 AG 3 ) 3 ] (telo21) via CD spectroscopy. Significant CD spectral changes of telo21 were observed in the presence of SYUIQ-5 (2.5 mM) (Figure 2a) , which indicated a possible decease of the parallel form of G-quadruplex DNA. Also, the binding affinity of SYUIQ-5 to a human telomeric sequence was studied by measuring the thermodynamic stability profile in the absence or presence of SYUIQ-5. We monitored a change of the absorption at 295 nm, which is a typical index for the conformational change from single-or double-stranded DNA to G-quadruplex DNA. Figure 2b showed the normalized CD intensity of telo21 at 295 nm against temperature, with 2.5 mM SYUIQ-5, in a Tris-HCl buffer (pH 7.4). The SYUIQ-5-induced antiparallel structure of telo21 melts at 531C, which was calculated from the CD melting curves at 295 nm using a nonlinear least-squares fitting. SYUIQ-5 was shown to increase the melting temperature of the G-quadruplex by about 131C, indicating a high affinity of SYUIQ-5 with the human telomeric sequence.
Inhibition of telomerase activity in K562 cell-free assay Initially, quindoline derivatives were evaluated in a polymerase chain reaction (PCR) to determine whether the compounds were nonspecific inhibitors of the reaction and would thereby score as 'false-positive' telomerase inhibitors in the telomeric report amplification protocol (TRAP). Our results indicated that there was no decrease in PCR product compared with 0.1% dimethyl sulfoxide (DMSO) in the presence of 1, 5 and 25 mM quindoline derivatives 4a-4j (data no shown). Subsequently, the effects of quindoline derivatives on telomerase activity were examined in cell-free system. In this experiment, solutions of quindoline derivatives were added to the telomerase reaction mixture containing extract from K562 cells, which express high levels of processive telomerase activity. Quindoline derivatives 4a-4j in vitro inhibited the process of telomerase in a dose-dependent manner with IC 50 values of 0.55, 1.12, 0.44, 2.35, 1.55, 4.38, 7.11, 3.29, 12.3 and 8 .12 mM, respectively (Table 1) . Hence, quindoline derivatives 4a-4j inhibited telomerase in the TRAP at concentrations below those shown to cause nonspecific inhibition of PCR system. Also, the internal control of the TRAP assay was used to determine the sensitivity of SYUIQ-5 and SYUIQ-7 (quindoline derivative 4i) for telomerase and Taq polymerase. As shown in Figure 3 , SYUIQ-5 inhibited telomerase activity remarkably, but SYUIQ-7 Figure 1 Structures of quindoline derivatives. (telo21) recorded under different conditions. CD spectra of telo21 with 100 mM Na þ (), 100 mM K þ (), telo21 only (À), and 2.5 mM SYUIQ-5( þ ). Telo21 tends to form antiparallel G-quadruplex in the presence of Na þ ions (curve ), while both parallel and antiparallel G-quadruplexes can be formed in the presence of K þ ions (curve ). Upon the addition of SYUIQ-5, the CD spectral at B250 nm was suppressed, indicating a possible decrease of the parallel form of G-quadruplex DNA. (b) CD melting profiles of telo21 with 2.5 mM SYUIQ-5. All the spectra were collected in a strand concentration of 5 mM in Tris-HCl buffer (pH 7.4). This experiment is a representative of three experiments. telomerase activity by SYUIQ-5 in whole cells parallels the relative potency of telomerase inhibition in the cellfree system.
Effect of SYUIQ-5 and SYUIQ-7 on K562 and SW620 cell viability To examine the long-term effect of SYUIQ-5 on K562 cells, concentrations of SYUIQ-5 was determined in which telomerase could be inhibited without extensive inhibition of cell proliferation firstly. Short-term cell viability was determined in a 3-day cytotoxic assay using various concentrations of SYUIQ-5. The IC 50 values of SYUIQ-5 for K562 cells and SW620 cells were 2.6570.15 and 1.6870.10 mM, respectively ( Figure 5 ). SYUIQ-5 had no effect on short-term cell viability or proliferation at concentrations of less than 0.5 mM in K562 cells or 0.3 mM in SW620 cells (data not shown). Therefore, 0.2 and 0.4 mM of SYUIQ-5 for K562 cells and 0.1 and 0.2 mM of SYUIQ-5 for SW620 cells were employed as the treatment concentrations in the following long-term cultivation experiments. Also, effect of SYUIQ-7 with greater IC 50 for telomerase on K562 and SW620 cell viability in a 3-day cytotoxic assay had been studied. The results showed that IC 50 values of SYUIQ-7 for K562 and SW620 cell lines were 4.0270.21 and 2.8970.19 mM, respectively. SYUIQ-7 had no effect on short-term cell viability or proliferation at concentrations of less than 0.8 mM in K562 cells or 0.4 mM in SW620 cells (data not shown). Therefore, 0.3 and 0.6 mM of SYUIQ-7 for K562 cells and 0.15 and 0.3 mM of SYUIQ-7 for SW620 cells were employed as the treatment concentrations in the following long-term cultivation experiments.
Senescence induced by SYUIQ-5
We characterized the growth properties of SYUIQ-5-treated cells. Treatment of K562 cells with SYUIQ-5 at 0.4 mM induced a plateau at day 28 on growth curves, followed by an arrest in cell growth at day 35 with typical figures of senescent cells. In contrast, cells treated with SYUIQ-5 at 0.2 mM were able to grow continuously after 35 days, but the population doubling time in 0.2 mM of SYUIQ-5 treatment group obviously increased (Figure 6a ). The similar results were observed in another human tumor cell line SW620 cells possessing relatively short telomeres, in which marked growth inhibition was observed at 16 days postincubation (Figure 6b ). In contrast, under nonacute toxic concentrations, SYUIQ-7 with greater IC 50 value for telomerase activity had no obvious effect of growth cessation on K562 cells and SW620 cells (Figure 6c and d) . Also, morphologic examination of the cells at the plateau phase showed an increased proportion of flat and giant cells with phenotypic characteristics of senescence and stained positively for the senescence-associated b-galactosidase (SA-b-gal) after continuous SYUIQ-5 treatment ( Figure 7 ).
Effect of SYUIQ-5 on telomere length
Inhibition of telomerase in cancer cells is predicted to disrupt telomere length maintenance and cause telomeres to erode. To investigate whether SYUIQ-5 can cause telomeres to shorten, telomere length was analysed using the TRF length assay. The results showed that 0.4 mM of SYUIQ-5 triggered significant telomere shortening about 6.1 kbp against K562 cells (Figure 8a ) and telomere shortening was also observed after 0.2 mM of SYUIQ-5 treatment. Similar reduction in telomere length was observed in SW620 cells. SYUIQ-5 (0.4 mM) caused telomere shortening of about 2.5 kbp against SW620 cells (Figure 8b ). As shown in Figure 8 , SW620 cells possess relatively short telomeres, but K562 cells possess relatively long telomeres. This result is consistent with the senescence induction experiment. Senescence induction in K562 cells required much longer time treatment than that in SW620 cells. However, reduction in telomere length was not observed after SYUIQ-7 treatment for 35 days (K562 cells) or 18 days (SW620 cells) (Figure 9 ). SYUIQ-5 induced the expression of p16, p21 and p27 Cyclin-dependent kinase inhibitors p16, p21 and p27 are regarded as key effectors of cellular senescence (Schwarze et al., 2001) . To identify whether p16, p21 and p27 were involved in SYUIQ-5-induced senescence, we tested expression of these proteins using immunoblot analysis. As shown in Figure 10 , p16, p21 and p27 were upregulated by SYUIQ-5 in K562 and SW620 cells, which suggested that growth arrest in K562 and SW620 cells induced by SYUIQ-5 could be mediated by the expression of p16, p21 and p27. 
Discussion
Telomerase is a ribonucleoprotein enzyme that maintains the protective structures at the ends of eukaryotic chromosomes, called telomeres (Bryan et al., 1997; Keith et al., 2001) . In most human somatic cells, telomerase expression is repressed, and telomeres shorten progressively with each cell division (Hahn et al., 1999) . In contrast, most human tumors express telomerase, resulting in stabilized telomere length. These observations indicate that telomere maintenance is essential for the proliferation of tumor cells (Bryan and Cech, 1999; Keith et al., 2001) . The telomeric ends of chromosomes consist of tandem repeats of simple guanine-rich DNA protein-associated motifs whose function is to protect the ends from unwanted DNA damage-repair, recombination and endfusions (Blackburn, 1991; Kelland, 2001 ). Folding of telomeric DNA into four-stranded structure involving G-quartets has been shown to inhibit the enzymes from catalysing the synthesis of telomeric DNA repeats. It is clear that synthetic molecules that induce and stabilise such G-quadruplex structures may be as effective as telomerase inhibitors Kerwin, 2000) .
Recently, a series of new quindoline derivatives have been designed and synthesized and they are not only able to stabilize G-quadruplex structure but also induce the G-rich telomeric repeats to fold into intramolecular antiparallel quadruplex. TRAP assay showed that the telomerase inhibition of quindoline derivatives were significantly improved comparing with quindoline ( Tel IC 50 >138 mM for quindoline, 0.44-12.3 mM for modified compounds 4a-4j). CD spectroscopy study clearly showed that SYUIQ-5 promoted the formation and stabilization of G-quadruplex of DNA and improved significant G4-stabilizing ability (increase of DT m values Senescence induced by SYUIQ-5 or SYUIQ-7 on K562 and SW620 cells. Long-term exposure with nonacute cytotoxic concentrations. Cells were exposed to indicated concentrations of SYUIQ-5, SYUIQ-7 or 0.1% DMSO, respectively. Every 3 or 4 days, the cells in control and drug-exposed flasks were trypsinized and counted using a hematocytometer and flasks reseeded with cells. Each experiment was performed three times at each point. This experiment is a representative of three experiments. by about 131C at 2.5 mM concentration). Taq polymerase was not inhibited at concentrations exceeding the 10 Â IC 50 value for telomerase and ITAS as internal control was unaffected under the concentrations that can inhibit telomerase activity significantly, suggesting that inhibition by SYUIQ-5 was highly selective for telomerase. One of these quindoline derivatives, SYUIQ-5, showed the most potent inhibitory effect, with 50% inhibition at 0.44 mM in the cell-free TRAP. In contrast to many G-quadruplex-based telomerase inhibitors described previously, SYUIQ-5 exhibited a wide difference between the potent inhibition of telomerase and acute cytotoxicity. SYUIQ-5 also displayed potent telomerase inhibitory activity in whole cancer cells. Treatment with SYUIQ-5 resulted in significant inhibition of telomerase activity. The extent of inhibition of telomerase activity by SYUIQ-5 in whole cancer cells parallels the relative potency of telomerase inhibition in the cell-free system. G-quadruplex-interacting compounds do not directly target telomerase but its substrates. G-quadruplex ligands are thought to inhibit the capacity of telomerase to elongate the telomeres of the cell but not to directly inhibit its telomerase activity as measured by the TRAP assay, which is based on the specific elongation of an external oligonucleotides mimicking telomere ends. However, like our results, several G-quadruplex ligands were reported to inhibit telomerase in treated cells (Izbicka et al., 1999; Grand et al., 2002; Riou et al., 2002) . The reason may be decreased hTERT expression in the treated cells (Figure 11 ) or decreased telomerase function through binding different associated proteins, such as hTERT and ubiquitin colocalization in the cytoplasm because of displacement from the 3 0 telomeric overhang (Burger et al., 2005) . Long-term exposure of cancer cells to nonacute cytotoxic concentrations of SYUIQ-5, SYUIQ-5 did not immediately cause a growth arrest. Instead, in the beginning cancer cells continued to proliferate, but the population doubling time increased, and finally the cells underwent growth arrest. Also, SAb-gal staining presented positive in growth arrest cells. However, did inhibition of telomerase activity influence telomere length? Long-term exposure of cancer cell lines to SYUIQ-5 resulted in reduction in telomere length. While, unlike most conventional chemotherapeutic agents, SYUIQ-5 did not induce cytotoxicity immediately after administration, and complete inhibition of cancer cell proliferation would require continued cell division until their telomeres reach a critically short length. These observations demonstrated that disruption of telomere maintenance limited cellular lifespan in cancer cells. As shown in Figure 8 , SW620 cells possesses shorter telomeres than K562 cells. It indicates that the cessation in growth of SW620 by SYUIQ-5 could require shorter time of treatment than in K562 cells. The results from long-term exposure experiments are consistent with the results of telomere length analysis. Senescence induction in K562 cells required much longer time treatment than that in SW620 cells. The two cell lines harboring different TRF length do not reach the same telomere lengths to enter senescence. Also, reduction of the TRF length in the two cell lines is not the same when they enter senescence. To confirm the cellular effects correlated with the IC 50 values of telomerase inhibition, cellular effect of SYUIQ-7 with greater IC 50 on cancer cell lines was conducted. Our results showed that SYUIQ-7 had no obvious cellular effect on senescence and TRF. It indicates that the cellular effect of SYUIQ-5 is associated with its function of telomerase inhibition. Cyclin-dependent kinase inhibitors p16, p21 and p27 are regarded as key effectors of cellular senescence (Schwarze et al., 2001) . The growth arrest in K562 and SW620 cells induced by SYUIQ-5 was accompanied by the upregulation of the expression of cyclin-dependent kinase inhibitors p16, p21 and p27. It indicates that p16, p21 and p27 could mediate the cessation of growth.
In conclusion, quindoline derivatives induced and stabilized intramolecular G-quadruplex structures. Treatment with SYUIQ-5 reproducibly inhibited telomerase activity in cancer cell lines, resulting in telomere shortening, followed by cellular senescence. These results from this study suggest that highly specific and novel potent G-quadruplex-interactive agents, quindoline derivatives (especially SYUIQ-5), could be promising agents for cancer treatment.
Materials and methods

Reagents and cell lines
The human leukemia cell line K562 and human colon cancer cell line SW620 were cultured in RPMI1640 medium and supplemented with 10% fetal bovine serum, penicillin (100 U/ ml) and streptomycin (100 mg/ml) at 371C in a 5% CO 2 humidified atmosphere. The p21, p27, p16 and hTERT antibodies used in this study were obtained from Santa Cruz. Drug stock solution was prepared by dissolving compounds in DMSO. The final concentration of DMSO in cultures was always less than 0.1% (v/v) and did not contribute to toxicity. All chemicals and reagents were purchased from Sigma Chemical Co.
Assay of interaction of small molecules with telomeric DNA The 21-mer oligonucleotide (G 3 (T 2 AG 3 )) 3 at a final concentration of 5 mM was resuspended in 10 mM Tris-HCl (pH 7.4) containing cations, drug or no. Samples were boiled for 5 min, placed on ice and annealed at 851C for 5 min, and then gradually cooled to room temperature. CD spectra were collected on a Jasco J-815 spectropolarimeter at 320-200 nm, using 16 scans at 100 nm/min, 1 s response time, and 1 nm bandwidth. Cuvettes of 1 mm width with black quartz sides to mask the light beam were used for the measurements. A buffer baseline was collected in the same cuvette and substracted from the sample spectra. Final spectra were normalized to have zero ellipticity at 320 nm.
Direct cell-free telomerase activity assay The ability of agents to inhibit telomerase activity in a cell-free assay was measured with a Telomerase PCR ELISA (Roche Molecular Biochemicals, Mannheim, Germany) according to the manufacturer's instructions. Approximately 2 Â 10 6 K562 cells were collected and washed by phosphate-buffered solution (PBS). Cell extracts were prepared as follows: pelleted cells were resuspended in 200 ml lysis reagent and incubated on ice for 30 min. Lysates were then centrifuged at 16 000 g for 20 min at 41C, and the supernatants removed and transferred to a fresh tube. For each sample to be tested, each tube contained 25 ml reaction mixture, 3 ml cell extract (corresponding to 3 Â 10 3 cell equivalents) and sterile water sufficient to provide a final volume of 50 ml. The elongation of telomeric DNA was conducted in 301C for 30 min. Then, amplification was performed by PCR (941C, 30 s; 501C, 30 s; 721C, 90 s; 31 cycles). After TRAP assay, an aliquot of the PCR product was denatured, hybridized to a digoxigenin (DIG)-labeled telomeric repeat-specific probe and bound to a streptavidin-coated 96-well plate. Finally, the immobilized PCR product was detected with an antibody against DIG that was conjugated to horseradish peroxidase (anti-DIG-HRP), visualized by a color reaction product using the substrate 3,3 0 ,5,5 0 -tetramethyl benzidine and semiquantified photometrically.
TRAP assay was performed as described above. After TRAP assay, 40 ml of the PCR reaction was separated on a 10% nondenaturing polyacrylamide gel (PAGE). Subsequently, gels were fixed, stained using AgNO 3 solution and photographed.
To exclude false-positive results due to Taq DNA polymerase inhibition eventually presented in the lysates, effect of test compounds on Taq DNA polymerase activity was conducted. Test compounds were added at concentrations of 1, 5 and 25 mM to a PCR 50 ml master mix containing 10 ng of DNA from SW620 cells and b-actin was amplificated using forward (5 0 -gtggataggccagcagtcat-3 0 ) and reverse primers (5 0 -tttgccttgtcagctgtgag-3 0 ). The product of approximately 546 bp was visualized using ethidium bromide after separation by electrophoresis on a 1.5% (w/v) agarose gel after amplification (30 cycles of 941C for 1 min, 551C for 1 min and 721C for 40 s) by using MJ thermal cycler.
Cell-based telomerase activity assay Cells were seeded on 12-well plates (5.0 Â 10 4 /well) and preincubated for 24 h at 371C in a humidified atmosphere of 5% CO 2 before exposure to various dilutions of SYUIQ-5 for 72 h. Cell extracts were prepared as described above for the standard cell-free assay. Concentrations of protein were determined using a BCA assay. Using equivalent total protein amounts, telomerase activity in each extract was determined by TRAP-ELISA as described above for the standard cell-free assay.
Short-term cell viability
Cells were seeded on 96-well plates (1.0 Â 10 3 /well) and preincubated for 24 h at 371C in a humidified atmosphere of 5% CO 2 before exposure to different dilutions of SYUIQ-5 for 68 h. A measure of 10 ml of MTT reagents (5 mg/ml) was added to each well, the cells were incubated for another 4 h at 371C, and then the liquid in the wells was evaporated. DMSO (200 ml) was added, and the absorbance (455/650 nm) was measured to estimate cell viability.
Long-term exposure studies Cells were grown in T80 tissue culture flasks at 1.0 Â 10 5 /flask and exposed to a nonacute cytotoxic concentration of or an equivalent volume of 0.1% DMSO every 3 or 4 days. The cells in control and drug-exposed flasks were trypsinized and counted using a hematocytometer and flasks reseeded with 1.0 Â 10 5 cells. Remaining cells were collected and used for measurements described below. This weekly process, with twice-weekly drug addition, was continued until such time that there were fewer than 1.0 Â 10 5 cells for reseeding.
Telomere length assay To measure the telomere length, genomic DNA was digested with Hinf1/Rsal restriction enzymes. The digested DNA fragments were separated on 0.8% agarose gel, transferred to a nylon membrane and the transferred DNA fixed on the wet blotting membrane by baking the membrane at 1201C for 20 min. Membrane was hybridized with a DIG-labeled hybridization probe for telomeric repeats and incubated with anti-DIG-alkaline phosphatase. TRF was performed by chemiluminescence detection.
Immunoblot analysis
After treatment, the cells were washed with PBS, and lysed in 100 ml of lysis buffer (10 mM Tris-HCl, pH 7.4, 5 mM MgCl 2 , 1 mM EDTA, 25 mM NaF, fresh 100 mM Na 3 VO 4 and l mM dithiothreitol). Cell lysates were centrifuged for 10 min at 14 000g. Concentrations of protein in the supernatant were determined by BCA protein assay. Equal amounts of protein (40 mg) were resolved on 10% SDS-PAGE, and transferred electrophoretically to PVDF membrane. The membranes were blocked with nonfat dry milk (5%) in TBST (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween-20), and then incubated with primary antibodies for 1 h at 41C, washed three times with TBST for 30 min, and then incubated with secondary antibody (horseradish peroxidase conjugated) for 2 h at room temperature. After washing the secondary antibody, the bound antibody complex was detected using an ECL chemiluminescence reagent.
SA-b-Gal assay
Cells treated with SYUIQ-5 were washed twice in PBS, fixed in 2% formaldehyde/0.2% glutaraldehyde for 5 min at room temperature, washed again in PBS, and incubated for 16 h with b-Gal stain solution containing 1 mg/ml 5-bromo-4-chloro-3-indolyl-b-D-galactoside, 40 mM citric acid/sodium phosphate, pH 6, 5 mM potassium ferrocynide, 5 mM ferricyanide, 150 nM NaCl and 2 mM MgCl 2 . Cells were viewed with use of a Zeiss light microscope and photographed.
